Takeda enlists Singapore's talent to drive forward vaccine development

Takeda’s (TYO: 4502) latest move to boost its fast-growing global vaccines business is to set up a Center of Excellence (CoE) in Singapore.

The Japanese drugmaker, which only set up its Global Vaccine Business Unit six years ago under the leadership of Rajeev Venkayya, has agreed a multi-year partnership with the Singapore Economic Development Board to support the recruitment and training of local talent in the development of new vaccine manufacturing technologies.

These recruits will work on Takeda’s current and future vaccines candidates, especially those to address diseases which present some of the world’s most challenging health problems, such as dengue, Zika and polio.